budesonide

Disclaimer to the Online Edition

This Manual has been designed for use in the NICU at London Health Sciences Centre (LHSC), London, Ontario, Canada, and represents clinical practice at this institution. The information contained within the Manual may not be applicable to other centres. If users of this Manual are not familiar with a drug, it is recommended that the official monograph be consulted before it is prescribed and administered. Any user of this information is advised that the contributors, Editor and LHSC are not responsible for any errors or omissions, and / or any consequences arising from the use of the information in this Manual.

budesonide

Indication

  • An inhaled corticosteroid used in the treatment of chronic lung disease 
  • Prevention of bronchopulmonary dysplasia (BPD) in patients on non-invasive respiratory support

Dosage Guidelines

Treatment of chronic lung disease

  • 0.5-1 mg q8-12 hours
  • Maximum dose 1 mg q12 hours

Prevention of BPD in patients on non-invasive respiratory support

  • 1 mg q12 hours (0800 and 2000) for 21 days followed by 1 mg q24 hours for 7 days
  • Assess response to therapy on day 7

Administration

  • Via nebulizer over 10-15 minutes
  • Dilute to a total of 3 mL with normal saline
  • Rinse or swab mouth with sterile water after administration to decrease the risk of oral candidiasis
  • Cover eyes during administration and wipe or rinse eyes after administration
  • May be mixed with salbutamol and ipratropium solutions just prior to administration

Adverse Effects

  • Sore throat, dysphonia, oral candidiasis

Comments

  • Monitor mouth/perineum for candidiasis
  • Onset: 24 hours
  • Maximum effect 3-7 days

Supplied As

  • 0.5 mg/mL nebuamp

References

  • Lexi Sick Kids, Lexi Peds